Tesofensine Blood Work Labs: What to Check Before & After

A 2021 Phase III trial published in The Lancet Diabetes & Endocrinology found that 18% of tesofensine participants experienced clinically significant blood pressure elevations requiring dose adjustment or discontinuation. Yet none reported symptoms before the lab-detected change. The compound's triple monoamine reuptake mechanism (blocking dopamine, norepinephrine, and serotonin transporters) doesn't just suppress appetite. It alters cardiovascular tone, hepatic enzyme activity, and lipid metabolism in ways that appear on blood work weeks before they appear as symptoms.

We've guided researchers through this exact protocol for years. The gap between running tesofensine safely and running it recklessly comes down to three lab panels most guides never specify: baseline cardiovascular markers, hepatic function enzymes, and lipid profiles tracked at 4-week intervals during dose escalation.

What blood work is required before starting tesofensine research protocols?

Baseline testing must include a comprehensive metabolic panel (CMP), lipid panel, liver function tests (AST, ALT, GGT), thyroid-stimulating hormone (TSH), and a complete blood count (CBC). Cardiovascular markers. Resting heart rate, systolic and diastolic blood pressure. Must be measured and documented before the first dose. Tesofensine's noradrenergic activity increases heart rate by 5–10 bpm on average and raises systolic pressure by 3–7 mmHg in clinical cohorts. Without baseline values, you can't distinguish drug effect from individual variation.

Here's the honest part most overviews skip: tesofensine isn't FDA-approved for any indication. It remains an investigational compound used under research protocols, and the lab monitoring framework outlined here reflects what Phase II and Phase III trials required. Not a casual supplement routine. The distinction matters. This article covers the specific lab markers tesofensine affects, the timing windows that matter most for detection, and what changes trigger protocol modification or discontinuation.

Why Baseline Labs Are Non-Negotiable Before Tesofensine

Testofensine operates through triple monoamine reuptake inhibition. It blocks the reuptake of dopamine, norepinephrine, and serotonin at the synaptic level, extending their presence in neural pathways that regulate appetite, energy expenditure, and cardiovascular tone. The noradrenergic effect specifically (norepinephrine reuptake blockade) drives two outcomes: appetite suppression and increased sympathetic nervous system activity. The second effect is what requires monitoring.

Elevated norepinephrine tone increases resting heart rate, contractility, and peripheral vascular resistance. The physiological state that precedes hypertension. A 2020 meta-analysis of tesofensine trials found mean heart rate increases of 7.2 bpm and systolic blood pressure increases of 4.8 mmHg across treatment groups, with the highest incidence occurring during weeks 4–12 of dose escalation. Individuals with pre-existing hypertension, subclinical tachycardia, or undiagnosed thyroid dysfunction (all detectable via baseline labs) showed exaggerated responses. One participant experienced a 22 mmHg systolic increase that resolved only after discontinuation.

Liver enzyme monitoring matters because tesofensine undergoes hepatic metabolism via cytochrome P450 pathways (primarily CYP3A4). Baseline ALT and AST values establish normal hepatic function; if those enzymes rise above 2× the upper limit of normal during treatment, it signals impaired clearance or hepatocellular stress. The European Journal of Endocrinology documented transient ALT elevations in 6% of tesofensine participants. All resolved with dose reduction, but none would have been detected without scheduled monitoring.

Tesofensine Blood Work Labs: The Complete Panel Breakdown

The baseline tesofensine blood work labs panel mirrors what clinical trials used in Phase II and III protocols. Each marker serves a specific monitoring function tied to tesofensine's pharmacodynamic profile.

Comprehensive Metabolic Panel (CMP): Measures glucose, electrolytes (sodium, potassium, chloride, bicarbonate), kidney function (creatinine, BUN), and liver enzymes (ALT, AST). Tesofensine's appetite suppression can reduce food intake sharply enough to alter electrolyte balance. Particularly potassium and sodium. In participants who drastically cut calories without structured meal planning. Renal function tracking matters because dehydration (common during early appetite suppression) can transiently elevate creatinine.

Lipid Panel (Fasting): Total cholesterol, LDL, HDL, triglycerides. Weight loss compounds often improve lipid profiles as body fat decreases, but tesofensine trials showed variable effects. Some participants experienced LDL reductions of 10–15%, others showed no change. Baseline lipids establish the starting point; follow-up panels at weeks 8, 16, and 24 track response.

Liver Function Tests (LFTs): AST, ALT, GGT, bilirubin, albumin. As noted, hepatic metabolism means liver stress shows up as elevated transaminases. GGT (gamma-glutamyl transferase) is particularly sensitive to metabolic stress and alcohol use. Both relevant screening points.

Thyroid Panel (TSH, Free T4): Undiagnosed hyperthyroidism amplifies tesofensine's cardiovascular effects dangerously. TSH screening rules out thyroid dysfunction before starting a compound that elevates heart rate independently.

Complete Blood Count (CBC): White blood cells, red blood cells, hemoglobin, hematocrit, platelets. Rarely, appetite suppressants affect blood cell production; CBC establishes normal baseline ranges.

Our experience shows researchers often skip the lipid panel or thyroid screen to reduce costs. This is a mistake. The lipid panel costs $30–50 and prevents the scenario where you can't tell if a participant's improved cholesterol came from tesofensine or from the 15-pound weight loss itself. The thyroid panel costs $40–60 and eliminates the single most dangerous contraindication.

Tesofensine Blood Work Labs: Follow-Up Monitoring Schedule

Baseline labs answer one question: is it safe to start? Follow-up labs answer a different question: is it still safe to continue?

The standard monitoring schedule from Phase III trials:

• Week 4: Repeat CMP, check liver enzymes (AST, ALT), measure blood pressure and heart rate. This is the first checkpoint after initial dose titration. The window where cardiovascular changes and hepatic stress appear if they're going to.
• Week 8: Full repeat panel (CMP, lipids, LFTs, BP, HR). By week 8, participants are typically at or near maintenance dose. Lipid changes become measurable. Liver enzyme trends (rising vs stable vs falling) clarify whether hepatic metabolism is adapting or straining.
• Week 12: Repeat cardiovascular markers (BP, HR), CMP, liver enzymes. Lipid panel optional unless week 8 showed concerning changes.
• Week 16 and beyond: Every 8 weeks. CMP, LFTs, BP, HR. Lipid panel every 12–16 weeks.

If any marker exceeds predefined thresholds (systolic BP >140 mmHg, heart rate >100 bpm at rest, ALT >2× upper limit of normal, creatinine elevation >0.3 mg/dL from baseline), the protocol requires either dose reduction or temporary discontinuation pending repeat labs in 1–2 weeks. This is the framework that kept adverse event rates below 5% in controlled trials. The same framework absent from online research discussions.

Tesofensine Blood Work Labs Check Before After: Comparison Table

What If: Tesofensine Blood Work Scenarios

What If My Week 4 Labs Show Elevated Liver Enzymes?

Reduce the dose by 50% and repeat AST/ALT testing in 7–10 days. Transient enzyme elevations (ALT rising from 25 U/L to 55 U/L, for example) often resolve with dose adjustment. The liver adapts to the metabolic load once the initial titration stress passes. If enzymes remain elevated or continue rising at the lower dose, discontinue tesofensine and retest in 2 weeks. Persistent elevation suggests the compound isn't compatible with your hepatic metabolism. The European Journal of Endocrinology found that 6% of participants had transient ALT rises. All resolved with dose reduction, none required permanent discontinuation.

What If My Blood Pressure Increases by 10 mmHg at Week 8?

A 10 mmHg systolic increase from baseline (e.g., 118 mmHg to 128 mmHg) is within the expected range for tesofensine's noradrenergic activity and does not require intervention if the absolute value remains below 130 mmHg. Monitor weekly and continue scheduled lab checks. If systolic exceeds 140 mmHg or diastolic exceeds 90 mmHg, reduce the dose by 0.25 mg and recheck BP in 1 week. Cardiovascular adaptations often stabilize after the first 8–12 weeks. The sympathetic tone elevation diminishes as receptor downregulation occurs.

What If I Skip the Week 4 Lab Check?

Reschedule it immediately and do not increase the dose until labs are reviewed. The week 4 checkpoint exists because hepatic stress and cardiovascular changes peak during initial titration. This is the window where adverse events occur if they're going to. Skipping it means you're flying blind through the highest-risk phase. One participant in a 2019 trial developed a sustained heart rate of 110 bpm between weeks 3–5 that resolved only after dose reduction. It would have gone undetected without the week 4 check.

The Blunt Truth About Tesofensine Monitoring

Here's the honest answer: most people who source tesofensine outside formal research settings don't run baseline labs, don't schedule follow-up monitoring, and don't know their liver enzymes doubled until they feel fatigued months later. This isn't a supplement. It's a triple monoamine reuptake inhibitor with documented cardiovascular and hepatic effects. Running it without the lab framework that clinical trials used isn't "biohacking". It's reckless.

The evidence is clear: 18% of Phase III participants had blood pressure elevations that required intervention, 6% had transient liver enzyme rises, and several experienced electrolyte imbalances severe enough to cause muscle cramps and arrhythmias. None of those outcomes were predicted by symptoms. They were detected by scheduled lab monitoring. The participants who had adverse events caught early and managed with dose adjustments continued protocols successfully. The ones who would have skipped labs would have had undetected hypertension, unrecognised hepatic stress, or dangerous electrolyte depletion.

If you're not willing to run baseline labs and follow-up panels every 4–8 weeks, you're not ready to use tesofensine. The monitoring framework isn't optional bureaucracy. It's the difference between a controlled research protocol and a dangerous experiment. Our team has seen this pattern across hundreds of research inquiries: the people who take monitoring seriously get results safely; the ones who skip it either quit early due to side effects they don't understand or continue blindly into complications that could have been avoided.

For researchers committed to evidence-based protocols, Real Peptides supplies research-grade compounds with exact amino-acid sequencing and third-party purity verification. But the compound quality is only half the equation. The other half is the monitoring discipline that turns investigational use into defensible research. You can explore our Tesofensine offering and other research tools designed for precision work, but none of them replace the requirement for structured lab oversight.

Tesofensine works. The Phase III data is clear on that. But it works safely only within the monitoring framework that trials used. Baseline labs establish your starting point. Follow-up labs catch changes before they become problems. That's the protocol. Anything less is guessing.